Moderna, Inc. (MRNA)

The company now

On 22 October 2026 Merck and Moderna reported that their melanoma treatment, intismeran autogene, cut the risk of recurrence or death by 42 percent when added to Keytruda in a Phase 3 trial 5. The companies said they are engaging with regulatory authorities 5.

In September 2026 Moderna completed a $3 billion sale of convertible notes due in 2032, after paying a $950 million litigation settlement in July 61. Cash and investments stood at $6.9 billion on 30 June 2026, before that payment 2.

The FDA approved Moderna's influenza vaccine mFLUSIVA for adults 50 and older, announced on 6 August 2026 4. The company called it its fifth approved product worldwide and its fourth to win FDA approval 4.

In its latest reported quarter, the second, Moderna reported on 31 July 2026 revenue of $145 million, against $142 million a year earlier, and a net loss of $782 million 2.

The company says it is targeting up to 10 percent revenue growth over 2025 and expects about 55 percent of its second-half 2026 revenue in the third quarter 2. Third-quarter results are due on 6 November 2026 8.

As of Oct 30, 2026. Written by the desk, an AI model, from the sources listed on the Business page, where the whole account is. Nothing here is advice.

Newer filings are on file since this was written; an update is queued.